55,206 Shares in Organon & Co. $OGN Bought by Citizens Financial Group Inc. RI

Citizens Financial Group Inc. RI bought a new position in shares of Organon & Co. (NYSE:OGN) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 55,206 shares of the company’s stock, valued at approximately $331,000.

A number of other institutional investors also recently bought and sold shares of the company. Farther Finance Advisors LLC increased its position in shares of Organon & Co. by 87.8% in the fourth quarter. Farther Finance Advisors LLC now owns 4,349 shares of the company’s stock valued at $31,000 after buying an additional 2,033 shares in the last quarter. Eurizon Capital SGR S.p.A. purchased a new stake in shares of Organon & Co. in the 4th quarter worth about $44,000. Kestra Advisory Services LLC purchased a new stake in shares of Organon & Co. in the 4th quarter worth about $47,000. Empowered Funds LLC acquired a new stake in Organon & Co. in the 4th quarter valued at about $74,000. Finally, Oxford Asset Management LLP acquired a new stake in Organon & Co. in the 4th quarter valued at about $74,000. 77.43% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Organon & Co. news, SVP Lynette Holzbaur purchased 26,448 shares of the business’s stock in a transaction on Wednesday, May 6th. The stock was bought at an average cost of $13.35 per share, for a total transaction of $353,080.80. Following the acquisition, the senior vice president owned 52,851 shares of the company’s stock, valued at approximately $705,560.85. The trade was a 100.17% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 1.62% of the company’s stock.

Organon & Co. Trading Up 0.1%

Shares of OGN stock opened at $13.51 on Friday. The company has a market capitalization of $3.55 billion, a price-to-earnings ratio of 14.52, a PEG ratio of 1.25 and a beta of 1.54. The company has a current ratio of 1.97, a quick ratio of 1.42 and a debt-to-equity ratio of 9.47. The firm has a 50-day moving average price of $13.44 and a 200 day moving average price of $9.96. Organon & Co. has a twelve month low of $5.69 and a twelve month high of $13.60.

Organon & Co. (NYSE:OGN) last released its quarterly earnings results on Thursday, April 30th. The company reported $0.71 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.83 by ($0.12). The firm had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.49 billion. Organon & Co. had a return on equity of 99.95% and a net margin of 3.99%.Organon & Co.’s revenue for the quarter was down 3.5% on a year-over-year basis. During the same period in the prior year, the business earned $1.02 earnings per share. Research analysts forecast that Organon & Co. will post 3.23 earnings per share for the current fiscal year.

Organon & Co. Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, June 11th. Investors of record on Monday, May 11th were given a dividend of $0.02 per share. The ex-dividend date was Monday, May 11th. This represents a $0.08 dividend on an annualized basis and a yield of 0.6%. Organon & Co.’s dividend payout ratio (DPR) is 8.60%.

Wall Street Analysts Forecast Growth

OGN has been the subject of several recent research reports. Zacks Research upgraded shares of Organon & Co. from a “strong sell” rating to a “hold” rating in a report on Tuesday, April 14th. Piper Sandler raised shares of Organon & Co. from an “underweight” rating to a “neutral” rating and upped their price target for the company from $5.00 to $14.00 in a report on Tuesday, April 28th. Weiss Ratings upgraded shares of Organon & Co. from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday. Finally, BNP Paribas Exane reissued a “neutral” rating and set a $14.00 price objective (up from $12.00) on shares of Organon & Co. in a research note on Wednesday, April 29th. Five investment analysts have rated the stock with a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Organon & Co. currently has a consensus rating of “Reduce” and a consensus target price of $11.40.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.